LATEST NEWS
Latest News
Latest News
THE OPHTHALMOLOGY MEDICINES COMPANY
Kodiak Sciences is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases
OUR MISSION
Kodiak aims to prevent and treat the leading causes of blindness in the developed world
TRAILBLAZING SCIENCE
OUR CREATIVE AND THOUGHTFUL FOUNDATION
“GO-TO” MEDICINES
OUR CHALLENGE TO THE STATUS QUO
SINGULAR FOCUS IN OPHTHALMOLOGY
OUR 24/7/365
OUR PRODUCT CANDIDATES
Three candidates advancing in parallel, collectively addressing the limitations of today’s therapies across a broad spectrum of retinal diseases
Tarcocimab Tedromer
High-prevalence retinal
vascular diseases
Wet AMD
Diabetic retinopathy
Retinal vein occlusion
Phase 3
KSI-501
High-prevalence retinal
vascular diseases
Indications of interest include wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy
Phase 3
KSI-101
Macular edema
secondary to inflammation
Phase 1b
Tarcocimab tedromer
Tarcocimab tedromer
Anti-VEGF ABC®
Anti-VEGF ABC
Tarcocimab is our most advanced program and one successful pivotal study away from a Biologic License Application (BLA) in 3 major retinal diseases.
Tarcocimab is an anti-VEGF Antibody Biopolymer Conjugate (ABC) being developed to provide strong immediacy and high durability in high-prevalence retinal vascular diseases. Across multiple studies, tarcocimab demonstrated consistent 6-month predominant durability and favorable safety. With a flexible 1-month through 6-month label, we believe tarcocimab can be the “mainstay” intravitreal biologic for all patients. Learn more
Tarcocimab is our most advanced program and one successful pivotal study away from a Biologic License Application (BLA) in 3 major retinal diseases.
Tarcocimab is an anti-VEGF Antibody Biopolymer Conjugate (ABC) being developed to provide strong immediacy and high durability in high-prevalence retinal vascular diseases. Across multiple studies, tarcocimab demonstrated consistent 6-month predominant durability and favorable safety. With a flexible 1-month through 6-month label, we believe tarcocimab can be the “mainstay” intravitreal biologic for all patients. Learn more
KSI-501
KSI-501
First-in-class, bispecific anti-IL-6, VEGF trap ABC®
First-in-class, bispecific anti-IL-6, VEGF trap ABC
KSI-501 is a bispecific Antibody Biopolymer Conjugate (ABC) designed to address two key unmet needs in high-prevalence retinal vascular diseases – higher efficacy and higher durability – by targeting retinal inflammation and vascular permeability simultaneously.
The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases. Learn more
KSI-501 is a bispecific Antibody Biopolymer Conjugate (ABC) designed to address two key unmet needs in high-prevalence retinal vascular diseases – higher efficacy and higher durability – by targeting retinal inflammation and vascular permeability simultaneously.
The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases. Learn more
KSI-101
KSI-101
First-in-class, bispecific anti-IL-6, VEGF trap protein
First-in-class, bispecific anti-IL-6, VEGF trap protein
KSI-101 is a potent 100 mg/mL high-strength bispecific protein being developed for the treatment of macular edema secondary to inflammation.
Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying disease mechanisms of IL-6-mediated inflammation and edema, and VEGF-mediated vascular permeability. Learn more
KSI-101 is a potent 100 mg/mL high-strength bispecific protein being developed for the treatment of macular edema secondary to inflammation.
Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying disease mechanisms of IL-6-mediated inflammation and edema, and VEGF-mediated vascular permeability. Learn more
Designed for high efficacy and high durability
Tarcocimab and KSI-501 are being developed as mainstay intravitreal biologic monotherapies that provide high efficacy and high durability with the ultimate objective of providing, once approved, a flexible 1-month through 6-month label
“Mainstay” intravitreal biologic monotherapies for all patients:
Gen 1.0: Eylea, Lucentis
Gen 1.5: Eylea HD, Vabysmo
Gen 2.0: Kodiak Investigational Medicines
- Tarcocimab: Strong immediacy and longest durability for all patients
- KSI-501: Potential for additional efficacy while maintaining signature durability of ABCD platform
“Alternative” therapies for different subset of patients after evaluating mainstay intravitreal biologics:
Implants: Tyrosine kinase inhibitor-based maintenance agents to be used after intravitreal biologic monotherapies have established disease control
Gene Therapies: Onerous monitoring and inflammation control. Long-term safety unknown
THE ABCD OF OUR SCIENCE
We are bringing new science to the design and development of next generation retinal medicines. Our Antibody Biopolymer Conjugate Drug (ABCD) Platform uses a bio-inspired polymer to enable multi-modal, multi-mechanistic treatment of complex ocular and systemic diseases
Antibody Biopolymer Conjugate Drug
Built-in durability
Designed to target multiple intracellular and extracellular mechanisms simultaneously
Designed for ocular and systemic diseases
OUR CULTURE AND VALUES
We are actively building a place, our Kodiak Village, where we are inspired, where we feel valued, and where we can grow our personal and professional journeys while advancing our mission. Historically referred to within Kodiak as the 4 C’s, our values are:
CURIOSITY
Staying fresh.
Asking why.
Being naturally inquisitive.
CREATIVITY
A safe place to think outside the box.
A focus on how to solve the problem.
COMPASSION
For ourselves.
For our colleagues.
For our patients.
COURAGE
Saying no when that’s the right answer.
Saying yes when that’s the right answer.
Regardless.
WORKING AT KODIAK
We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas.
